Emerald Advisers LLC bought a new stake in shares of Savara Inc (NASDAQ:SVRA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 2,332,680 shares of the company's stock, valued at approximately $7,161,000. Emerald Advisers LLC owned 1.36% of Savara as of its most recent SEC filing.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Cibc World Markets Corp purchased a new stake in Savara in the 4th quarter valued at about $33,000. KLP Kapitalforvaltning AS bought a new stake in shares of Savara during the fourth quarter valued at about $41,000. Virtu Financial LLC bought a new stake in Savara during the 3rd quarter worth approximately $67,000. BNP Paribas Financial Markets raised its position in shares of Savara by 258.9% in the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company's stock worth $109,000 after buying an additional 18,534 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Savara by 14.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company's stock valued at $112,000 after acquiring an additional 4,732 shares during the last quarter. Institutional investors own 87.93% of the company's stock.
Wall Street Analyst Weigh In
SVRA has been the topic of a number of recent research reports. JMP Securities reiterated a "market outperform" rating and set a $9.00 price target on shares of Savara in a research report on Thursday, December 19th. Wells Fargo & Company began coverage on Savara in a research note on Friday, December 20th. They issued an "overweight" rating and a $8.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.83.
View Our Latest Analysis on SVRA
Savara Price Performance
Shares of SVRA stock traded up $0.08 during trading hours on Thursday, hitting $2.78. The stock had a trading volume of 1,107,180 shares, compared to its average volume of 1,289,476. The stock has a market capitalization of $477.10 million, a price-to-earnings ratio of -6.47 and a beta of 0.60. Savara Inc has a one year low of $2.26 and a one year high of $5.34. The stock's 50-day moving average price is $2.72 and its two-hundred day moving average price is $3.27. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70.
About Savara
(
Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Further Reading
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
